Cipla gets final approval from USFDA for Albuterol Sulfate Inhalation Aerosol

Cipla Ltd on Thursday said it has received final approval from the US health regulator forAlbuterol Sulfate Inhalation Aerosolused in the treatment of acute episodes of bronchospasm or prevention of asthmatic symptoms.

In a regulatory filing the company said "it has received final approval for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfate Inhalation Aerosol 90mcg (base)/actuation, from the United States Food and Drug Administration (US FDA)."